Prostate cancer news report: Sunday, January 24, 2010

In this weekend’s prostate cancer news reports, we have addressed recent publications on:

  • A SNP that may be specifically linked to risk for prostate cancer in African Americans
  • The need for extended biopsies in men with larger prostates who are considering focal treatment for prostate cancer
  • A possible association between diabetes, race, obesity, and risk for prostate cancer progression
  • Neoadjuvant hormone therapy, brachytherapy, and all cause mortality in older patients … READ MORE …

Neoadjuvant chemohormonal therapy in high-risk prostate cancer patients

It is clear from a report in the December issue of Urologic Oncology that the neoadjuvant use of chemohormonal therapy prior to surgery or radiation is not going to be a “cure-all” for prostate cancer patients initially diagnosed with high-risk, locally advanced prostate cancer. … READ MORE …

Hormone therapy and radiation treatment: a topical update

There are several recent reports that address factors specific to the combination of hormone therapy with radiation therapy in the management of prostate cancer, so we thought it would be helpful to offer a topical update. … READ MORE …

Radiotherapy + ADT following radical prostatectomy

A Canadian group has just added a little more to our knowledge about the role of neoadjuvant hormone therapy in association with radiotherapy after first-line radical prostatectomy (RP). … READ MORE …

Neoadjuvant paclitaxel before surgery in high risk, locally advanced patients

A group at the Cleveland Clinic has reported the results of a small, single-arm, Phase II trial of neoadjuvant albumin-bound paclitaxel (nab-paclitaxel or neoadjuvant Abraxane®), given prior to radical prostatectomy in high risk, locally advanced patients. Prior comparable studies with neoadjuvant docetaxel have demonstrated a PSA response but have shown no obvious antitumor activity. … READ MORE …

Hormone therapy + radiotherapy as first-line treatment: how long do you need hormones?

Here’s a question that comes up over and over again from newly diagnosed patients: “My doctor is suggesting I get hormones in  combination with radiation therapy. How long am I likely to be on hormone therapy?” … READ MORE …

Neoadjuvant hormone therapy in localized and locally advanced prostate cancer

The Cochrane Collaboration is a highly respected global network that seeks to improve healthcare decision-making through systematic reviews of the effects of healthcare interventions, published in The Cochrane Library. The Cochrane Urological Cancers Unit has just published a detailed review and assessment of the value of hormone therapy in neoadjuvant management of localized and locally advanced prostate cancer. … READ MORE …